Browse > Article
http://dx.doi.org/10.4062/biomolther.2009.17.4.370

NDRG2 Expression Increases Apoptosis Induced by Doxorubicin in Malignant Breast Caner Cells  

Kim, Myung-Jin (Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University)
Kang, Kyeong-Ah (Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University)
Yang, Young (Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University)
Lim, Jong-Seok (Department of Biological Science and the Research Center for Women's Diseases, Sookmyung Women's University)
Publication Information
Biomolecules & Therapeutics / v.17, no.4, 2009 , pp. 370-378 More about this Journal
Abstract
N-myc downstream-regulated gene 2 (NDRG2) has recently been found to be a tumor suppressor gene. Although it has been reported that NDRG2 expression in breast cancer cells decreases cell proliferation by inhibiting STAT3 activation via SOCS1 induction, the molecular mechanism of chemotherapeutic agent-induced apoptosis is not well known. To elucidate the effect of NDRG2 on the apoptotic pathway induced by doxorubicin, we established stable cell lines expressing NDRG2 and investigated the effect of NDRG2 expression on the doxorubicin-induced apoptosis. While STAT3 activation was remarkably inhibited by NDRG2 overexpression, the expression level of p21 was increased by NDRG2 expression. We confirmed that NDRG2-expressing cells treated with doxorubicin suppressed STAT3 activation and upregulated p21 expression. NDRG2 expression considerably enhanced TUNEL positive apoptotic cells, poly-ADP ribose polymerase (PARP) cleavage, release of cytochrome c to cytosol, and caspase-3 activity in doxorubicin-induced apoptosis. Bid expression in a resting state and after treatment with doxorubicin increased in MDA-MB-231-NDRG2 cells compared to MDA-MB-231-mock cells. Meanwhile, Bcl-$x_L$ expression decreased in MDA-MB-231-NDRG2 cells compared to MDA-MB-231-mock cells in a resting state and in doxorubicin-treated cells. Collectively, these data suggest that suppression of STAT3 activation by NDRG2 influences the sensitivity to doxorubicin-induced apoptosis of breast cancer cells and this may provide a potential therapeutic benefit to overcome the resistance against doxorubicin in breast cancer.
Keywords
N-myc downstream-regulated gene 2 (NDRG2); Doxorubicin; Breast cancer; Apoptosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
1 Lusis, E. A., Watson, M. A., Chicoine, M. R., Lyman, M., Roerig, P., Reifenberger, G., Gutmann, D. H. and Perry, A. (2005). Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 65, 7121- 7126.   DOI   ScienceOn
2 Qu, X., Zhai, Y., Wei, H., Zhang, C., Xing, G., Yu, Y. and He, F. (2002). Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell. Biochem. 229, 35-44.   DOI   ScienceOn
3 Wang, Y. A., Johnson, S. K., Brown, B. L., McCarragher, L. M., Al-Sakkaf, K., Royds, J. A. and Dobson, P. R. (2008). Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int. J. Cancer 123, 1536-1544.   DOI   ScienceOn
4 Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro- Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A. and Jove, R. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513.   DOI
5 Ishii, Y., Waxman, S. and Germain, D. (2008). Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res. 68, 852-860.   DOI   ScienceOn
6 Lachat, P., Shaw, P., Gebhard, S., van Belzen, N., Chaubert, P. and Bosman, F. T. (2002). Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem. Cell Biol. 118, 399-408.   DOI
7 Deng, Y., Yao, L., Chau, L., Ng, S. S., Peng, Y., Liu, X., Au, W. S., Wang, J., Li, F., Ji, S., Han, H., Nie, X., Li, Q., Kung, H. F., Leung, S. Y. and Lin, M. C. (2003). N-Myc downstreamregulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int. J. Cancer 106, 342-347.   DOI   ScienceOn
8 Zhou, R. H., Kokame, K., Tsukamoto, Y., Yutani, C., Kato, H. and Miyata, T. (2001). Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73, 86-97.   DOI   ScienceOn
9 Johnstone, R. W., Ruefli, A. A. and Lowe, S. W. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164.   DOI   ScienceOn
10 Kim, Y. J., Yoon, S. Y., Kim, J. T., Choi, S. C., Lim, J. S., Kim, J. H., Song, E. Y., Lee, H. G., Choi, I. and Kim, J. W. (2008). NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int. J. Cancer 124, 7-15.   DOI   ScienceOn
11 Lui, N., Wang, L., Li, X., Yang, Q., Liu, X., Zhang, J., Zhang, J., Wu, Y., Ji, S., Zhang, Y., Yang, A., Han, H. and Yao, L. (2008). N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucl. Acid Res. 36, 5335-5349.   DOI   ScienceOn
12 Okuda, T. and Kondoh, H. (1999). Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc. Biochem. Biophys. Res. Commun. 266, 208-215.   DOI   ScienceOn
13 Park, Y., Shon, S. K., Kim, A., Kim, K. I., Yang, Y., Cho, D. H., Lee, M. S. and Lim, J. S. (2007). SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem. Biophys. Res. Commun. 363, 361-367.   DOI   ScienceOn
14 Swift, L. P., Cutts, S. M., Nudelman, A., Levovich, I., Rephaeli, A. and Phillips, D. R. (2008). The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother. Pharmacol. 61, 739-749.   DOI
15 Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R. and Loughran, T. P. Jr. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107, 351- 362.   DOI   ScienceOn
16 Choi, S. C., Yoon, S. R., Park, Y. P., Song, E. Y., Kim, J. W., Kim, W. H., Yang, Y., Lim, J. S. and Lee, H. G. (2007). Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp. Mol. Med. 39, 705-714.   DOI   ScienceOn
17 Costantino, L. and Barlocco, D. (2008). STAT 3 as a target for cancer drug discovery. Curr. Med. Chem. 15, 834-843.   DOI   ScienceOn
18 Decker, P. and Muller, S. (2002). Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotech. 3, 275-283.   DOI   ScienceOn
19 Fornari, F. A., Randolph, J. K., Yalowich, J. C., Ritke, M. K. and Gewirtz, D. A. (1994). Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 45, 649-656.
20 Gariboldi, M. B., Ravizza, R., Molteni, R., Osella, D., Gabano, E. and Monti, E. (2007). Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 258, 181-188.   DOI   ScienceOn
21 Ghobrial, I. M., Witzig, T. E. and Adjei, A. A. (2005). Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194.   DOI   ScienceOn
22 Aggarwal, B. B., Sethi, G., Ahn, K. S., Sandur, S. K., Pandey, M. K., Kunnumakkara, A. B., Sung, B. and Ichikawa, H. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci. 1091, 151-169.   DOI   ScienceOn
23 Hu, X. L., Liu, X. P., Lin, S. X., Deng, Y. C., Liu, N., Li, X. and Yao, L. B. (2004). NDRG2 expression and mutation in human liver and pancreatic cancers. World J. Gastroenterol. 10, 3518-3521.   DOI